Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

73.86 +0.39 (+0.54%)
Streaming Delayed Price Updated: 9:57 AM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Monday Morning
Via Investor Brand Network
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Thursday Morning
Via Investor Brand Network
Drivers And Stock Pickers
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient. 
Via Talk Markets
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
Are these frigid Dow stocks in for a longer winter?
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
3 companies that more than doubled analyst EPS estimates
Earning season is well underway, and the separation between the winners and losers continues to grow. Of the companies that have beat 
Via MarketBeat
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024." 
Via Benzinga
Merck Animal Health to Acquire Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
7 Mutual Funds That Will Outperform in Any Market
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds. 
Via InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Merck Stock Rocketed Nearly 5% Skyward Today
The company reported healthy sales growth and proffered encouraging guidance to boot. 
Via The Motley Fool
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... 
Via Benzinga
Exposures COVID-19
Merck (MRK) Q4 2023 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024. 
Via Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. 
Via Benzinga
Merck Reports A Surprise Profit As Keytruda Sales Continue On Their Warpath
Analysts expected an 11-cent per-share loss from Merck in the fourth quarter. But the company came out ahead. 
Via Investor's Business Daily
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.